SG11202007554TA - Dioxazoline compound, preparation method therefor, and uses thereof - Google Patents

Dioxazoline compound, preparation method therefor, and uses thereof

Info

Publication number
SG11202007554TA
SG11202007554TA SG11202007554TA SG11202007554TA SG11202007554TA SG 11202007554T A SG11202007554T A SG 11202007554TA SG 11202007554T A SG11202007554T A SG 11202007554TA SG 11202007554T A SG11202007554T A SG 11202007554TA SG 11202007554T A SG11202007554T A SG 11202007554TA
Authority
SG
Singapore
Prior art keywords
preparation
method therefor
dioxazoline compound
dioxazoline
compound
Prior art date
Application number
SG11202007554TA
Inventor
Qiang Zhang
Shannan Yu
Zhongxiang Wang
Shouye Feng
Yueming Sun
Yansheng Liu
Hongbo Zhang
Leifu Yang
Hailong Yang
Likai Zhou
Nanqiao Zheng
Chenming Hu
Zhanqiang Xu
Original Assignee
Beijing Scitech Mq Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076233 external-priority patent/WO2018153293A1/en
Application filed by Beijing Scitech Mq Pharmaceuticals Ltd filed Critical Beijing Scitech Mq Pharmaceuticals Ltd
Priority claimed from PCT/CN2019/073260 external-priority patent/WO2019154133A1/en
Publication of SG11202007554TA publication Critical patent/SG11202007554TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
SG11202007554TA 2017-02-27 2019-01-25 Dioxazoline compound, preparation method therefor, and uses thereof SG11202007554TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201710107756 2017-02-27
PCT/CN2018/076233 WO2018153293A1 (en) 2017-02-27 2018-02-11 Dioxanoquinazoline, dioxanoquinazoline-type compound, preparation method therefor and use thereof
CN201810983341.3A CN110156803A (en) 2017-02-27 2018-08-27 Dioxanes and quinolines and the preparation method and application thereof
PCT/CN2019/073260 WO2019154133A1 (en) 2018-02-11 2019-01-25 Dioxazoline compound, preparation method therefor, and uses thereof

Publications (1)

Publication Number Publication Date
SG11202007554TA true SG11202007554TA (en) 2020-09-29

Family

ID=63374400

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007554TA SG11202007554TA (en) 2017-02-27 2019-01-25 Dioxazoline compound, preparation method therefor, and uses thereof

Country Status (5)

Country Link
CN (3) CN108503650B (en)
AU (1) AU2019218187B2 (en)
DK (1) DK3750893T3 (en)
ES (1) ES2945573T3 (en)
SG (1) SG11202007554TA (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11731946B2 (en) 2017-10-19 2023-08-22 The General Hospital Corporation Broad spectrum antivirulence, anti-persistence compounds
CN110156804B (en) * 2018-02-11 2021-01-12 北京赛特明强医药科技有限公司 Dioxane quinoline compound and preparation method thereof
CN111196814B (en) * 2018-11-19 2022-12-06 北京赛特明强医药科技有限公司 Aromatic ring-linked dioxane quinazoline or quinoline compound, composition and application thereof
CN111004257B (en) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 Method for preparing RET inhibitor Selpercatinib
CN112939995A (en) * 2021-02-02 2021-06-11 北京工业大学 Process for preparing dioxanoquinazoline derivatives
CN114957136A (en) * 2021-02-24 2022-08-30 南京科默生物医药有限公司 Anti-tumor compound used as VEGFR inhibitor and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
EA027476B1 (en) * 2010-09-27 2017-07-31 Экселиксис, Инк. Use of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
CN104530063B (en) * 2015-01-13 2017-01-18 北京赛特明强医药科技有限公司 Quinazoline and heterocyclic ring compounds, preparing method of compounds, and application of compounds serving as epidermal growth factor receptor inhibitors used for treating cancer
CN106279147A (en) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 A kind of pyrido nitrogen heterocyclic and its production and use
CN105837586B (en) * 2015-12-14 2018-02-13 北京赛特明强医药科技有限公司 Dioxane and quinazoline aminated compounds and preparation method thereof and the application as epidermal growth factor receptor inhibitor
CN105541798B (en) * 2016-02-03 2018-01-23 中国人民解放军第二军医大学 Quinolines Mutiple Targets kinase inhibitor with antitumor activity and preparation method thereof
WO2018153293A1 (en) * 2017-02-27 2018-08-30 北京赛特明强医药科技有限公司 Dioxanoquinazoline, dioxanoquinazoline-type compound, preparation method therefor and use thereof

Also Published As

Publication number Publication date
DK3750893T3 (en) 2023-05-08
CN111788207B (en) 2021-03-23
CN111788207A (en) 2020-10-16
AU2019218187A1 (en) 2020-09-10
ES2945573T3 (en) 2023-07-04
CN110156803A (en) 2019-08-23
AU2019218187B2 (en) 2021-10-14
CN108503650B (en) 2021-02-12
CN108503650A (en) 2018-09-07

Similar Documents

Publication Publication Date Title
IL272089A (en) Compounds, compositions and methods
HUE062446T2 (en) Compounds, compositions and methods
EP3299369A4 (en) Pyrido-azaheterecydic compound and preparation method and use thereof
HK1247205A1 (en) Allyl-phenoxy-cyclophosphazene compound, and production method therefor
GB2557741B (en) Icariside compound, preperation method thereof, and application thereof
EP3246327A4 (en) 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof
SG11202007554TA (en) Dioxazoline compound, preparation method therefor, and uses thereof
EP3372596A4 (en) Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor
SG11202007521PA (en) Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof
HK1255559A1 (en) Mg53 mutant, and preparation method therefor and uses thereof
PT3552017T (en) Compounds, compositions and methods
EP3715342A4 (en) Fluorosulfonyl-containing compound, intermediate thereof, preparation method therefor and use thereof
HK1243437A1 (en) Tripeptide compound, preparation method therefor, and application thereof
EP3447054A4 (en) Compound and preparation method therefor, composition and application thereof
EP3543248A4 (en) PHOSPHORESCENT PtAg2 COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOF
EP3112351A4 (en) Naphthylamide compound, preparation method and use thereof
IL282817A (en) Novel compound, preparation method and application thereof
GB2564511B (en) Composition, method and use
GB201805016D0 (en) Composition, method and use
EP3581561A4 (en) Biaryl compound, preparation method and use therefor
GB201705124D0 (en) Composition, method and use
EP3392263A4 (en) Polypeptide compound, preparation method therefor and use thereof
PL3760633T3 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
EP3564215A4 (en) Polyhydroxyphthalazinone compound, preparation method therefor and use thereof
PL3750893T3 (en) Dioxazoline compound, preparation method therefor, and uses thereof